Treatment outcomes in REM sleep behavior disorder

Stuart J. McCarter, Christopher L. Boswell, Erik K St Louis, Lucas G. Dueffert, Nancy Slocumb, Bradley F Boeve, Michael H. Silber, Eric J. Olson, Maja Tippmann-Peikert

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Objective: REM sleep behavior disorder (RBD) is usually characterized by potentially injurious dream enactment behaviors (DEB). RBD treatment aims to reduce DEBs and prevent injury, but outcomes require further elucidation. We surveyed RBD patients to describe longitudinal treatment outcomes with melatonin and clonazepam. Methods: We surveyed and reviewed records of consecutive RBD patients seen at Mayo Clinic between 2008-2010 to describe RBD-related injury frequency-severity as well as RBD visual analog scale (VAS) ratings, medication dosage, and side effects. Statistical analyses were performed with appropriate non-parametric matched pairs tests before and after treatment, and with comparative group analyses for continuous and categorical variables between treatment groups. The primary outcome variables were RBD VAS ratings and injury frequency. Results: Forty-five (84.9%) of 53 respondent surveys were analyzed. Mean age was 65.8years and 35 (77.8%) patients were men. Neurodegenerative disorders were seen in 24 (53%) patients and 25 (56%) received antidepressants. Twenty-five patients received melatonin, 18 received clonazepam, and two received both as initial treatment. Before treatment, 27 patients (60%) reported an RBD associated injury. Median dosages were melatonin 6mg and clonazepam 0.5mg. RBD VAS ratings were significantly improved following both treatments (pm=0.0001, pc=0.0005). Melatonin-treated patients reported significantly reduced injuries (pm=0.001, pc=0.06) and fewer adverse effects (p=0.07). Mean durations of treatment were no different between groups (for clonazepam 53.9±29.5months, and for melatonin 27.4±24months, p=0.13) and there were no differences in treatment retention, with 28% of melatonin and 22% of clonazepam-treated patients discontinuing treatment (p=0.43). Conclusions: Melatonin and clonazepam were each reported to reduce RBD behaviors and injuries and appeared comparably effective in our naturalistic practice experience. Melatonin-treated patients reported less frequent adverse effects than those treated with clonazepam. More effective treatments that would eliminate injury potential and evidence-based treatment outcomes from prospective clinical trials for RBD are needed.

Original languageEnglish (US)
Pages (from-to)237-242
Number of pages6
JournalSleep Medicine
Volume14
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

REM Sleep Behavior Disorder
Clonazepam
Melatonin
Wounds and Injuries
Visual Analog Scale
Therapeutics
Neurodegenerative Diseases
Antidepressive Agents

Keywords

  • Clonazepam
  • Falls
  • Injury
  • Melatonin
  • Parasomnia
  • REM sleep behavior disorder
  • Retention
  • Side effects
  • Synucleinopathy
  • Tolerability
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

McCarter, S. J., Boswell, C. L., St Louis, E. K., Dueffert, L. G., Slocumb, N., Boeve, B. F., ... Tippmann-Peikert, M. (2013). Treatment outcomes in REM sleep behavior disorder. Sleep Medicine, 14(3), 237-242. https://doi.org/10.1016/j.sleep.2012.09.018

Treatment outcomes in REM sleep behavior disorder. / McCarter, Stuart J.; Boswell, Christopher L.; St Louis, Erik K; Dueffert, Lucas G.; Slocumb, Nancy; Boeve, Bradley F; Silber, Michael H.; Olson, Eric J.; Tippmann-Peikert, Maja.

In: Sleep Medicine, Vol. 14, No. 3, 03.2013, p. 237-242.

Research output: Contribution to journalArticle

McCarter, SJ, Boswell, CL, St Louis, EK, Dueffert, LG, Slocumb, N, Boeve, BF, Silber, MH, Olson, EJ & Tippmann-Peikert, M 2013, 'Treatment outcomes in REM sleep behavior disorder', Sleep Medicine, vol. 14, no. 3, pp. 237-242. https://doi.org/10.1016/j.sleep.2012.09.018
McCarter, Stuart J. ; Boswell, Christopher L. ; St Louis, Erik K ; Dueffert, Lucas G. ; Slocumb, Nancy ; Boeve, Bradley F ; Silber, Michael H. ; Olson, Eric J. ; Tippmann-Peikert, Maja. / Treatment outcomes in REM sleep behavior disorder. In: Sleep Medicine. 2013 ; Vol. 14, No. 3. pp. 237-242.
@article{feb85a44507c4a609a72ec72ac77c753,
title = "Treatment outcomes in REM sleep behavior disorder",
abstract = "Objective: REM sleep behavior disorder (RBD) is usually characterized by potentially injurious dream enactment behaviors (DEB). RBD treatment aims to reduce DEBs and prevent injury, but outcomes require further elucidation. We surveyed RBD patients to describe longitudinal treatment outcomes with melatonin and clonazepam. Methods: We surveyed and reviewed records of consecutive RBD patients seen at Mayo Clinic between 2008-2010 to describe RBD-related injury frequency-severity as well as RBD visual analog scale (VAS) ratings, medication dosage, and side effects. Statistical analyses were performed with appropriate non-parametric matched pairs tests before and after treatment, and with comparative group analyses for continuous and categorical variables between treatment groups. The primary outcome variables were RBD VAS ratings and injury frequency. Results: Forty-five (84.9{\%}) of 53 respondent surveys were analyzed. Mean age was 65.8years and 35 (77.8{\%}) patients were men. Neurodegenerative disorders were seen in 24 (53{\%}) patients and 25 (56{\%}) received antidepressants. Twenty-five patients received melatonin, 18 received clonazepam, and two received both as initial treatment. Before treatment, 27 patients (60{\%}) reported an RBD associated injury. Median dosages were melatonin 6mg and clonazepam 0.5mg. RBD VAS ratings were significantly improved following both treatments (pm=0.0001, pc=0.0005). Melatonin-treated patients reported significantly reduced injuries (pm=0.001, pc=0.06) and fewer adverse effects (p=0.07). Mean durations of treatment were no different between groups (for clonazepam 53.9±29.5months, and for melatonin 27.4±24months, p=0.13) and there were no differences in treatment retention, with 28{\%} of melatonin and 22{\%} of clonazepam-treated patients discontinuing treatment (p=0.43). Conclusions: Melatonin and clonazepam were each reported to reduce RBD behaviors and injuries and appeared comparably effective in our naturalistic practice experience. Melatonin-treated patients reported less frequent adverse effects than those treated with clonazepam. More effective treatments that would eliminate injury potential and evidence-based treatment outcomes from prospective clinical trials for RBD are needed.",
keywords = "Clonazepam, Falls, Injury, Melatonin, Parasomnia, REM sleep behavior disorder, Retention, Side effects, Synucleinopathy, Tolerability, Treatment",
author = "McCarter, {Stuart J.} and Boswell, {Christopher L.} and {St Louis}, {Erik K} and Dueffert, {Lucas G.} and Nancy Slocumb and Boeve, {Bradley F} and Silber, {Michael H.} and Olson, {Eric J.} and Maja Tippmann-Peikert",
year = "2013",
month = "3",
doi = "10.1016/j.sleep.2012.09.018",
language = "English (US)",
volume = "14",
pages = "237--242",
journal = "Sleep Medicine",
issn = "1389-9457",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Treatment outcomes in REM sleep behavior disorder

AU - McCarter, Stuart J.

AU - Boswell, Christopher L.

AU - St Louis, Erik K

AU - Dueffert, Lucas G.

AU - Slocumb, Nancy

AU - Boeve, Bradley F

AU - Silber, Michael H.

AU - Olson, Eric J.

AU - Tippmann-Peikert, Maja

PY - 2013/3

Y1 - 2013/3

N2 - Objective: REM sleep behavior disorder (RBD) is usually characterized by potentially injurious dream enactment behaviors (DEB). RBD treatment aims to reduce DEBs and prevent injury, but outcomes require further elucidation. We surveyed RBD patients to describe longitudinal treatment outcomes with melatonin and clonazepam. Methods: We surveyed and reviewed records of consecutive RBD patients seen at Mayo Clinic between 2008-2010 to describe RBD-related injury frequency-severity as well as RBD visual analog scale (VAS) ratings, medication dosage, and side effects. Statistical analyses were performed with appropriate non-parametric matched pairs tests before and after treatment, and with comparative group analyses for continuous and categorical variables between treatment groups. The primary outcome variables were RBD VAS ratings and injury frequency. Results: Forty-five (84.9%) of 53 respondent surveys were analyzed. Mean age was 65.8years and 35 (77.8%) patients were men. Neurodegenerative disorders were seen in 24 (53%) patients and 25 (56%) received antidepressants. Twenty-five patients received melatonin, 18 received clonazepam, and two received both as initial treatment. Before treatment, 27 patients (60%) reported an RBD associated injury. Median dosages were melatonin 6mg and clonazepam 0.5mg. RBD VAS ratings were significantly improved following both treatments (pm=0.0001, pc=0.0005). Melatonin-treated patients reported significantly reduced injuries (pm=0.001, pc=0.06) and fewer adverse effects (p=0.07). Mean durations of treatment were no different between groups (for clonazepam 53.9±29.5months, and for melatonin 27.4±24months, p=0.13) and there were no differences in treatment retention, with 28% of melatonin and 22% of clonazepam-treated patients discontinuing treatment (p=0.43). Conclusions: Melatonin and clonazepam were each reported to reduce RBD behaviors and injuries and appeared comparably effective in our naturalistic practice experience. Melatonin-treated patients reported less frequent adverse effects than those treated with clonazepam. More effective treatments that would eliminate injury potential and evidence-based treatment outcomes from prospective clinical trials for RBD are needed.

AB - Objective: REM sleep behavior disorder (RBD) is usually characterized by potentially injurious dream enactment behaviors (DEB). RBD treatment aims to reduce DEBs and prevent injury, but outcomes require further elucidation. We surveyed RBD patients to describe longitudinal treatment outcomes with melatonin and clonazepam. Methods: We surveyed and reviewed records of consecutive RBD patients seen at Mayo Clinic between 2008-2010 to describe RBD-related injury frequency-severity as well as RBD visual analog scale (VAS) ratings, medication dosage, and side effects. Statistical analyses were performed with appropriate non-parametric matched pairs tests before and after treatment, and with comparative group analyses for continuous and categorical variables between treatment groups. The primary outcome variables were RBD VAS ratings and injury frequency. Results: Forty-five (84.9%) of 53 respondent surveys were analyzed. Mean age was 65.8years and 35 (77.8%) patients were men. Neurodegenerative disorders were seen in 24 (53%) patients and 25 (56%) received antidepressants. Twenty-five patients received melatonin, 18 received clonazepam, and two received both as initial treatment. Before treatment, 27 patients (60%) reported an RBD associated injury. Median dosages were melatonin 6mg and clonazepam 0.5mg. RBD VAS ratings were significantly improved following both treatments (pm=0.0001, pc=0.0005). Melatonin-treated patients reported significantly reduced injuries (pm=0.001, pc=0.06) and fewer adverse effects (p=0.07). Mean durations of treatment were no different between groups (for clonazepam 53.9±29.5months, and for melatonin 27.4±24months, p=0.13) and there were no differences in treatment retention, with 28% of melatonin and 22% of clonazepam-treated patients discontinuing treatment (p=0.43). Conclusions: Melatonin and clonazepam were each reported to reduce RBD behaviors and injuries and appeared comparably effective in our naturalistic practice experience. Melatonin-treated patients reported less frequent adverse effects than those treated with clonazepam. More effective treatments that would eliminate injury potential and evidence-based treatment outcomes from prospective clinical trials for RBD are needed.

KW - Clonazepam

KW - Falls

KW - Injury

KW - Melatonin

KW - Parasomnia

KW - REM sleep behavior disorder

KW - Retention

KW - Side effects

KW - Synucleinopathy

KW - Tolerability

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84874262357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874262357&partnerID=8YFLogxK

U2 - 10.1016/j.sleep.2012.09.018

DO - 10.1016/j.sleep.2012.09.018

M3 - Article

C2 - 23352028

AN - SCOPUS:84874262357

VL - 14

SP - 237

EP - 242

JO - Sleep Medicine

JF - Sleep Medicine

SN - 1389-9457

IS - 3

ER -